Reports of calciphylaxis or calcific uremic arteriolopathy associated with acral and gastrointestinal involvement are rare. We describe a 36-year-old white woman with end-stage renal disease on hemodialysis after failed kidney and pancreas transplantation who developed dry gangrene of bilateral digits, osteomyelitis, and small bowel ischemia within several months of each presentation. She had multiple débridements of a septic right ankle. Computed tomography angiography showed severe vascular calcification and pneumatosis intestinalis. She underwent intestinal resection for gangrenous small bowel. A multidisciplinary approach with aggressive medical and surgical management may improve survival. Our case and the literature confirm the high morbidity of patients with calciphylaxis and vascular complications. 
subsequent failure of the kidney transplant, underwent right triple arthrodesis with a right midtarsal arthrodesis and an Achilles tendon lengthening in 2014. Six months before her last hospitalization, she developed a septic right ankle and underwent removal of the hardware for a Charcot midfoot. She had a 6-week course of intravenous ertapenem for Streptococcus mitis and Klebsiella pneumoniae. She underwent placement of a right ankle spatial frame for loss of bone and antibiotic beads for persistent infection from Klebsiella oxytoca and Enterococcus faecalis (Fig 1) . Additional wound culture showed Stenotrophomonas (Xanthomonas) maltophilia. She declined amputation of her right foot.
The patient developed a 3-month history of intermittent paresthesia, worsening pallor, and eventual dry gangrene of the fingers (Fig 2) . The vascular surgery service was consulted for evaluation of painful, gangrenous hands and left foot. Anklebrachial index showed incompressible vessels with absent perfusion of the digits and toes. Computed tomography (CT) angiography (Fig 3) showed circumferential calcified atherosclerotic disease of the ulnar, radial, and interosseous arteries and mesenteric vessels. Significant laboratory studies showed low glomerular filtration rate of 11 mL/min/1.73 m 2 , elevated parathyroid level of 28 pg/mL, and high phosphorus level of 5.6 mg/dL.
The diagnosis of calciphylaxis was determined on the basis of clinical presentation. Two months later, the patient presented to the emergency department with a 2-day history of diffuse abdominal pain associated with nausea, vomiting, nonbloody diarrhea, fever, and Pathologic examination showed transmural ischemic necrosis with ulceration, perforation, and acute peritonitis. She was discharged home 2 weeks later.
Six months after her initial presentation of septic arthritis, 3 months after digital gangrene, and 2 months after ischemic bowel, the patient developed leukocytosis, hypotension, and decubitus ulcer. She was readmitted for infection of the right foot, treated with antibiotics, and discharged 2 weeks before her death at home on December 30, 2017. Consent for publication was obtained from the patient before her death.
DISCUSSION
Also known as calcific uremic arteriolopathy, calciphylaxis was first characterized by Selye et al 1 in 1961 as a hypersensitivity reaction in rodents resulting in calcification of skin and skeletal muscles. It is a devastating disease with an estimated prevalence of 4.1% in hemodialysis patients and mortality of 60% within 1 year due to infections. 2, 3 The mechanism of arterial calcification is a dynamic and active process that shares common grounds with normal bone mineralization. 4 Under the influence of b-glycerophosphate, smooth muscle cells can undergo osteoblastic differentiation, resulting in a favorable environment for mineralization. 4 Calcification occurs in the intimal layer, leading to atherosclerotic plaque and a decreased luminal area, and in the medial layer, resulting in loss of arterial compliance. 5 Histologic features include small-and medium-vessel medial calcification with intimal calcium deposits associated with dermal angioplasia and thrombosis. There is no histologic difference between patients with and patients without chronic kidney disease. 4 Common presentation of calciphylaxis includes painful and nonhealing wounds that can result in black eschar and secondary superinfection. 6 Most commonly, these lesions occur in adipose-rich areas, such as trunk, buttocks, and thighs, although acral and penile involvement has also been reported. [7] [8] [9] Ocular, cardiovascular, pulmonary, and gastrointestinal system complications are extremely rare, with fewer than 10 reported cases of gastrointestinal involvement in calciphylaxis. 7, 8, [10] [11] [12] [13] Risk factors for calciphylaxis include hyperparathyroidism, elevated calcium-phosphorus product, chronic kidney disease, diabetes, female sex, warfarin use, and obesity. 9 Diagnosis of calciphylaxis is clinically supported by skin biopsy as the "gold standard." However, normal findings on skin biopsy do not rule out calciphylaxis because only 18% of 56 biopsy specimens from confirmed patients showed classic features of calcification of the arterioles. 2 Hayashi 6 proposed the use of histopathologic findings for calciphylaxis only if three of the clinical findings are not present: chronic hemodialysis or glomerular filtration rate <15 mL/min/1.73 m 2 ; more than two painful and nontreatable skin ulcers; and ulcers on trunk, extremities, or penis. The high mortality rate of calciphylaxis is most often associated with infection of nonhealing wounds leading to sepsis, with 1-year survival <50% and 2-year survival <20%.
2 Gastrointestinal involvement of calciphylaxis is extremely rare with grim outcome. 7,8,10-13 A case report described a 63-year-old woman who presented with skin lesions of bilateral calves, single-digit discoloration of the left hand, and abdominal pain, with CT confirming colonic perforation. 12 Another case report described a 66-year-old woman with black necrotic eschar on bilateral lower extremities, lower gastrointestinal bleed, and rectal necrosis. 13 The patients of both cases died of sepsis and multiorgan failure. Although skin biopsy may confirm diagnosis of calciphylaxis, we advise clinicians to use caution regarding skin biopsy and invasive treatments because of poor healing and increased risk of sepsis. 6 Current mainstays of treatment are mostly supportive, including pain control, wound care, intravenous sodium thiosulfate, correction of calcium and phosphorus levels, bisphosphonates, vitamin K, and full-intensity anticoagulation. 2 Patecki et al 9 recommended bone biopsy in patients with calciphylaxis to dictate therapy after determination of the level of bone turnover. The benefit of kidney transplantation in calciphylaxis remains unclear, and diverging results after renal transplantation have been reported. 2 An observational study proposed that intralesional sodium thiosulfate injections rather than intravenous infusions may be an effective treatment of skin lesions due to calciphylaxis; however, this recommendation was based on four patients, and a case report showed that needle injections led to abscess formation and worsening of skin lesions. 14 Hyperbaric oxygen therapy (HBOT) is associated with better wound healing and extended survival time in >50% of patients with an average of 44 treatments; diabetes was the only factor that significantly influenced wound healing and mortality. 15 Use of sodium thiosulfate with HBOT has also been suggested to have a synergistic effect, but concrete data are needed for recommendation. 16 The role of revascularization for wound healing in calciphylaxis is insufficiently studied with no definitive recommendations. Furthermore, vascular procedures are a negative determinant of survival in patients with calciphylaxis. 17 Multiple studies suggest that treatment of calciphylaxis is multimodal, and early initiation of such therapies is instrumental in achieving the best patient outcome. 2, 6, 16 Finally, because of the high mortality and morbidity associated with calciphylaxis, it is important to initiate early conversations of disease prognosis and approach to therapy with patients and their families so that their priorities can be factored in when management is being planned. 2 Finally, it is important to address end-of-life issues with such patients because of the high mortality and morbidity associated with calciphylaxis.
CONCLUSIONS
This patient has multiple risk factors and clinical presentation for calciphylaxis. Noninvasive arterial studies and CT angiography demonstrating incompressible vessels and vascular calcifications further solidify the diagnosis of calcific uremic arteriolopathy. HBOT and sodium thiosulfate may be considered viable therapies. A multidisciplinary approach with aggressive medical and surgical management may improve survival. Our case and the literature confirm the high morbidity of patients with calciphylaxis and vascular complications. Careful follow-up remains necessary for diagnosis and management to prevent complication, infection, and death.
